Oral bioavailable ITRI-148 degrades androgen receptor variants and overcomes antiandrogen resistance in advanced prostate cancer.
口服生物利用度高的 ITRI-148 可降解雄激素受体变体，克服晚期前列腺癌的抗雄激素耐药性。
期刊:Neoplasia
影响因子:7.7
doi:10.1016/j.neo.2025.101253
Hung Chiu-Lien, Hsu Wen-Ning, Wang Tsan-Chun, Chen Wan-Ru, Chen Yu-Ting, Kuo Zong-Keng, Hu Tsan-Lin, Lin Yu-Chin, Yeh Hsun-Hao, Lin Han-Chen, Yu Chia-Jung, Fu Chih-Wei, Liu Hao-Hsuan, Hsu Hung-Chih, Lin Po-Hung, Pang See-Tong, Lai Chih-Ho, Wang Ling-Yu
